Paclitaxel and carboplatin in treatment of advanced non-small cell lung cancer: preliminary results of open prospective randomized clinical study

Gorbunova V.A., Marenich A.F., Reutova E.V., Sheveleva L.P., Karaseva N.A., Bogdanova N.V., Uskov D.A., Hasanov R.Sh., Muhametshina G.Z., Tuzikov S.A., Horinko A.V., Ivanov R.A., Par V.I.

Ronts. N.N. Blokhina RAMN, Moscow. Volgograd regional clinical oncological clinic № 1, Volgograd. City Oncology center, St. Petersburg. Moscow research oncological Institute. P.A. Herzen Russian medical technologies, Moscow. Moscow regional Oncology center MOH MOE, Moscow. Clinical Oncology center, Kazan. Institute of Oncology, Tomsk scientific center, SB RAMS, Tomsk. Perm regional Oncology center, Perm ZAO “Biocad”.
There are presented results of research on the safety evaluation of drugs Tacsakad (paclitaxel and Carboplatin in combination chemotherapy in 40 patients with disseminated small cell lung cancer, as well as the effectiveness of the treatment. Patients held from 1 to 6 cycles of chemotherapy on the proposed scheme (Tacsakad dose of 175 mg/m2 as a 3-hour intravenous infusion and Carboplatin in a dose corresponding to AUC = 6) at intervals of 21 days. Anemia III-IV degrees registered 5.0 % of cases, lakopenia III-IV degrees - 10.0 %, neutropenia III-IV degrees - 40.0 %, thrombocytopenia III-IV degrees - in 2.5 % of patients. Cases raising the level of the hepatic markers and creatinine, relevant toxicity III-IV degrees, were noted. Frequency of achieving a partial response was 20,0, stabilization - 57,1 %. Obtained data allow to speak that the scheme of combined chemotherapy on the basis of generic drugs Tacsakad and Carboplatin the effectiveness of similar schemes on the basis of original drugs.

Similar Articles

Бионика Медиа